ELC Group appoints former TOPRA president

Dr Paolo Biffignandi joins ELC Group’s Advisory Board

Dr Paolo Biffignandi, former president of The Organisation for Professionals in Regulatory Affairs (TOPRA), has joined the ELC Group’s Advisory Board. ELC is a pan-European pharmaceutical regulatory affairs organisation.

Dr Biffignandi, a renowned physician, with PhDs in endocrinology and pharmacology, is a Fellow of TOPRA, as well as an Overseas Fellow of the Royal Society of Medicine (UK). He brings more than 30 years' experience in Regulatory Affairs and pharmacovigilance to ELC Group’s Advisory Board.

Commenting on his appointment, Dr Biffignandi said: 'ELC Group is the industry expert, and I'm pleased to accept this opportunity to join its Advisory Board and to contribute to its continued strategic success.'

You may also like

Regulatory

ELC Group signs €1.5m regulatory affairs contract with Chinese pharma company

Endorses its Concept to Commercialisation approach to regulatory affairs consultancy services
Regulatory

ELC Group expands corporate presence in Czech Republic

Major contract wins in China and US fuel latest move into larger premises in Prague
Regulatory

ELC Group expands its offices in Ahmedabad, India

Regulatory affairs specialist continues its growth in the country
Regulatory

ELC Group opens new office in Mumbai, India

To be headed by Pooja Raj, general manager, regulatory affairs
Regulatory

ELC Group establishes global hq in Cambridge, UK

Follows year of exceptional revenue growth for regulatory affairs organisation
Regulatory

AstraZeneca's New Drug Application for hypertension drug accepted under FDA Priority Review

Baxdrostat has had positive Phase III trial results and, if approved, could be the first aldosterone synthase inhibitor to receive regulatory authorisation
Regulatory

NOAH calls for Veterinary Medicines Agreement amid concerns over Northern Ireland veterinary medicines supply changes

With EU regulations set to apply fully from 1 January 2026, Northern Ireland could see 10-15% of veterinary medicines discontinued. Industry and government are working on mitigation schemes to protect animal health and ensure continued access to essential treatments
Subscribe now